Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Vampire bat bite packs potent clot-busting potential for strokes

10.01.2003


A potent clot-busting substance originally extracted from the saliva of vampire bats may be used up to three times longer than the current stroke treatment window – without increasing the risk for additional brain damage, according to research reported in today’s rapid access issue of Stroke: Journal of the American Heart Association.



The vampire bat saliva-derived clot buster is called Desmodus rotundus salivary plasminogen activator (DSPA) or desmoteplase. DSPA targets and destroys fibrin, the structural scaffold of blood clots, says senior author Robert Medcalf, Ph.D. NH & MRC senior research fellow at Monash University Department of Medicine at Box Hill Hospital in Victoria, Australia.

"When the vampire bat bites its victim, it secretes this powerful clot-dissolving (fibrinolytic) substance so that the victim’s blood will keep flowing, allowing the bat to feed," Medcalf explains.


In the mid-1980s, Wolf-Dieter Schleuning, M.D., Ph.D., now chief scientific officer of the German biotechnological company PAION GmbH, found that the vampire bat enzyme was genetically related to the clot buster tissue plasminogen activator (t-PA) but was more potent. Medcalf and Schleuning were pioneers in the cloning and the study of gene expression of t-PA and were among the first scientists to spot its potential use for heart attack.

The only Food and Drug Administration-approved clot buster for treating ischemic stroke is intravenous recombinant tissue plasminogen activator, (rt-PA). Ischemic strokes are caused when a blood clot or series of clots block blood supply to the brain. rt-PA is administered to a small percentage of stroke patients because current protocols allow treatment only within three hours of stroke onset. Also, rt-PA has been shown to promote brain cell death in some animal studies.

The clot-busting activity of DSPA increases about 13,000-fold when exposed to fibrin. The activity of rt-PA increases only 72-fold when exposed to fibrin.

Researchers injected either DSPA or rt-PA into the brains of mice, then tracked the survival of brain cells. They discovered that while DSPA zeros in on fibrin, it had no affect on two brain receptors that can promote brain damage, Medcalf says. In contrast, rt-PA greatly enhanced the degree of brain cell death following receptor activation and may therefore be detrimental if it’s delivered too long after stroke onset.

The highly fibrin-specific activity demonstrated by DSPA may be an important advantage over rt-PA. It is this single-minded clot-busting action that has stroke researchers especially intrigued because while rt-PA is effective at breaking up and dissolving clots, it must be given quickly – within just three hours of the onset of stroke symptoms. By contrast, Medcalf says DSPA could be a safe treatment option for a longer period since it has no detrimental effect on brain cells. The three-hour time window often allows insufficient time for patients to undergo imaging tests to determine that they have a true ischemic stroke before rt-PA can initiated, he says.

"This report provides data suggesting a potential advantage of a type of plasminogen activator derived from bat saliva over t-PA, the only FDA-approved treatment for selected patients with acute ischemic stroke," says Larry Goldstein, M.D., chairperson of the American Stroke Association Advisory Committee. "It needs to be understood that this study is limited to mice without stroke and focused only on toxicity. Whether this approach will prove either safe or efficacious in improving stroke outcomes requires further testing."

Goldstein is director of the Center for Cerebrovascular Disease at Duke University in Durham, N.C.

DSPA is being tested up to nine hours after stroke onset in human stroke patients in Europe, Asia and Australia. A U.S. study could begin this year, Schleuning says. Other co-authors are Gabriel T. Liberatore, Ph.D, André Samson; and Christopher Bladin, M.D.


###
CONTACT: For journal copies only,
please call: (214) 706-1396
For other information, call:
Carole Bullock: (214) 706-1279
Bridgette McNeill: (214) 706-1135

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>